OncoSil Medical (ASX:OSL) secured UK Conformity Assessed renewal certificates from the British Standards Institution (BSI) for its OncoSil pancreatic cancer treatment device, according to a Monday filing with the Australian Securities Exchange.

The certification allows the company to have continued access to the UK market without additional compliance burdens, the filing said.

The company is also expecting to receive Medical Device Regulation approval from BSI shortly, according to the filing.

Shares rose more than 8% in afternoon trade.